EP1592450A2 - Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions - Google Patents
Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositionsInfo
- Publication number
- EP1592450A2 EP1592450A2 EP04710907A EP04710907A EP1592450A2 EP 1592450 A2 EP1592450 A2 EP 1592450A2 EP 04710907 A EP04710907 A EP 04710907A EP 04710907 A EP04710907 A EP 04710907A EP 1592450 A2 EP1592450 A2 EP 1592450A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- carrier liquid
- pharmaceutical composition
- liquid
- pharmaceutical
- mbar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 36
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 8
- 238000009835 boiling Methods 0.000 claims abstract description 7
- 239000004615 ingredient Substances 0.000 claims abstract description 7
- 239000012620 biological material Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 35
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 7
- 229960002715 nicotine Drugs 0.000 claims description 7
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 7
- NOPJRYAFUXTDLX-UHFFFAOYSA-N 1,1,1,2,2,3,3-heptafluoro-3-methoxypropane Chemical compound COC(F)(F)C(F)(F)C(F)(F)F NOPJRYAFUXTDLX-UHFFFAOYSA-N 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- OKIYQFLILPKULA-UHFFFAOYSA-N 1,1,1,2,2,3,3,4,4-nonafluoro-4-methoxybutane Chemical compound COC(F)(F)C(F)(F)C(F)(F)C(F)(F)F OKIYQFLILPKULA-UHFFFAOYSA-N 0.000 claims description 5
- DFUYAWQUODQGFF-UHFFFAOYSA-N 1-ethoxy-1,1,2,2,3,3,4,4,4-nonafluorobutane Chemical compound CCOC(F)(F)C(F)(F)C(F)(F)C(F)(F)F DFUYAWQUODQGFF-UHFFFAOYSA-N 0.000 claims description 5
- -1 vaccines Substances 0.000 claims description 5
- 239000000824 cytostatic agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 102000004877 Insulin Human genes 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 13
- 210000004400 mucous membrane Anatomy 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 239000003380 propellant Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000002009 allergenic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 210000002255 anal canal Anatomy 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/124—Aerosols; Foams characterised by the propellant
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the invention relates to the use of a volatile liquid at atmospheric pressure and at room temperature for the manufacture of a pharmaceutical and / or biological composition. It also relates to the pharmaceutical composition comprising such a liquid.
- compositions are formulated to be taken orally, and they consist of an ingredient, therapeutically active, solid, coated in solid excipients. However, these compositions have a slow therapeutic effect.
- compositions are formulated to be injected into the patient's body, in which case the active ingredient is immediately released into the body.
- injectable pharmaceutical compositions are not always tolerated by the patient either because the liquid vehicle in which they are dissolved is itself toxic, or, as for diabetics, that the injections are to be repeated very often, which doesn is not always compatible with the lifestyle of patients.
- compositions for dermatological use which are formulated in the form of an ointment, gel or liquid to be applied to the skin.
- excipients in which these compositions are formulated can be toxic or allergenic and cause harmful reactions.
- compositions which can be administered by application to the mucous membranes, in particular to the nasal mucous membranes.
- Such formulations contain the active ingredient in liquid form and a propellant to bring the active ingredient and its vehicle to the nasal mucosa.
- the active ingredient is often brought into the airways and lungs of the patient and this type of composition is used only when such delivery in the airways and lungs is necessary.
- compositions currently in existence are formulated in the form of a suppository for rectal administration or in the form of an ovum for vaginal administration.
- the active ingredient passes through the mucosa, anal or vaginal respectively.
- compositions sometimes poorly accepted by the patient have several drawbacks.
- the excipient melts and causes unpleasant and messy discharge, and, on the other hand, they tend to leave the anal canal or the vagina. This phenomenon is accentuated in the case of suppositories, which induce a defecation reflex, especially in children. In this case, the drug is not administered.
- compositions in particular comprising hormones or nicotine are currently used in the form of a patch to be applied to the skin for release through the skin barrier.
- the formulation of the composition to be applied to the patch poses many problems due to the instability of the hormones in current formulations.
- compositions of the care product indeed, some care products must be administered only on the burn site without spilling over into healthy areas, or to be treated in a different way. This is particularly the case for pharmaceutical compositions formulated as an ointment or liquid.
- compositions for repairing living tissue consist of stem cells which are grown in an adequate culture medium.
- the stem cells are harvested and immediately put in the culture medium for growth. It is not known at the present time to maintain these stem cells at an intermediate growth stage, without evolution until the desired final growth and to maintain them healthy at this intermediate growth stage.
- an example is, in particular for an application for burn victims, the growth of human skin in situ: the stem cells are harvested and grown in situ in their culture medium until the culture medium is removed and , thus, the growth stopped. It could be advantageous to be able to grow these skin cells in vitro, and to block the growth of these cells at a certain stage, in order to be able to transplant them in situ, when the other serious burn treatments have been sufficiently advanced to allow a such transplant. Likewise, tests for the absence of toxicity and of absence of an allergic type reaction for pharmaceutical compositions and cosmetic compositions are increasingly carried out on artificial skins cultivated in vitro, instead of being tested on animals or human being. It would thus be advantageous, for greater reactivity, to be able to have human skin stem cells blocked at a certain stage of growth and kept healthy, which could then be allowed to grow until the formation of the skin tissue to achieve testing the compositions on fresh human skin tissue as discussed above.
- the invention aims to solve the problems of pharmaceutical or biological compositions of the prior art by providing such compositions which are in a biocompatible carrier liquid, without toxicity towards humans and cytostatic, and whose volatility is elevated at room temperature and at atmospheric pressure.
- a liquid which is a perfluorine compound having a vapor pressure at 25 ° C and at atmospheric pressure greater than or equal to 10,000 Pa (100 mbar) and a boiling point greater than or equal at 30 ° C. in the manufacture of a pharmaceutical and / or biological composition consisting solely of this liquid and of the pharmaceutical ingredient in the form of powder and / or of the solid biological material, the pharmaceutical ingredient and / or the biological material being insoluble in the liquid, and possibly a film-forming agent.
- the liquid has a vapor pressure at 25 ° C and at atmospheric pressure between 10,000 Pa (100 mbar) and 70,000 Pa (700 mbar).
- the liquid is a hydrofluoroether (HFE), a mixture of the isomers of a hydrofluoroether and a mixture of hydrofluoroethers (HFE) of formula (1) below:
- R H denotes a substituted or unsubstituted, linear, branched or cyclic, partially or completely hydrogenated alkyl radical
- R F denotes a linear, branched or cyclic, totally or partially fluorinated alkyl radical.
- the liquid is chosen from the group consisting of methoxyheptafluoropropane, ethoxynonafluorobutane and methoxynonafluorobutane.
- the liquid constitutes the cytostatic preservation medium for stem cells from human, animal or plant tissues.
- the stem cells are stem cells from human skin tissue.
- the liquid is the carrier liquid of a pharmaceutical composition in which the active ingredient is in the form of a micronized powder insoluble in the carrier liquid.
- a second subject of the invention is a pharmaceutical composition of the type comprising an active ingredient and a carrier liquid which consists of a carrier liquid which is a perfluorine compound which has a vapor pressure at 25 ° C. and at atmospheric pressure greater than or equal to 10,000 Pa (100 mbar) and a boiling point greater than or equal to 30 ° C and a therapeutically active ingredient in the form of a micronized powder insoluble in the carrier liquid, and optionally a film-forming agent.
- the carrier liquid has a vapor pressure at 25 ° C and at atmospheric pressure between 10,000 Pa (100 mbar) and 70,000 Pa (700 mbar).
- the carrier liquid is a hydrofluoroether, a mixture of the isomers of a hydrofluoroether and a mixture of hydrofluoroethers of the following formula 1:
- R H denotes a substituted or unsubstituted, linear, branched or cyclic, partially or completely hydrogenated alkyl radical
- R denotes a linear, branched or cyclic, totally or partially fluorinated alkyl radical.
- the radical R F can have several position isomers.
- hydrofluoroether encompasses both a hydrofluoroether of which the RH and R radicals, each independently, are present in a single isomeric form as a hydrofluoroether of which the RH radical and / or the RH radicals are present, each independently, in the form of a mixture of two or more of their isomeric forms.
- mixture of hydrofluoroethers include mixtures of two or more hydrofluoroethers having different RH and R radicals but each RH and RF radical, each independently, being in a single isomeric form or as a mixture of several of their isomeric forms.
- the carrier liquid is chosen from the group consisting of methoxyheptafluoropropane, ethoxynonafluorobutane and methoxynonafluorobutane.
- the active ingredient it is particularly selected insulin, vaccines, analgesics, nitroglycerin ®, nicotine, iodine, hormones, antibiotics and antibacterial agents.
- the volume ratio of the active ingredient to the carrier liquid is between 1/4 and 4/1 inclusive.
- the volume ratio of the active ingredient to the carrier liquid is 1/1.
- the pharmaceutical composition is packaged in a sprayer.
- it contains a film-forming agent.
- a third subject of the invention relates to the use of the pharmaceutical composition of the invention for the care of burn victims.
- the invention relates to pharmaceutical compositions which must be rapidly delivered into the blood or lymphatic or other system of the body, which is generally achieved by injection by syringe.
- the invention proposes to maintain the active ingredient in solid form, or to put it in solid form, as by lyophilization, and to apply it to the mucous membranes.
- the active ingredient in powder form must be a micronized powder and must be deposited on the mucous membranes, in particular the nasal membranes.
- the active ingredient in the form of micronized powder is propelled by a propellant under pressure, which limits its use to the active ingredients which can be and / or have to be transmitted in the airways and the lungs, which limits its use.
- the active ingredient will not be propelled by a propellant gas but will simply be deposited at the precise site of use, that is to say the mucous membranes, without being propelled in the airways and the lungs, thanks to the use of a very volatile carrier at room temperature and at atmospheric pressure which is in liquid form.
- Such a carrier liquid has a vapor pressure at 25 ° C and atmospheric pressure greater than or equal to 10,000 Pa (100 mbar), preferably between 10,000 Pa (100 mbar) and 70,000 Pa (700 mbar) and must have a boiling point greater than or equal to 30 ° C. Indeed, with a boiling temperature below 30 ° C, the carrier liquid would no longer be in liquid form at room temperature but in gaseous form or in the form of a liquid-gas mixture and we would then find the related problem using a propellant gas.
- this support is a mucous membrane of a human or animal
- such sudden cooling can cause undesirable phenomena such as vasoconstriction, or discomfort in administration.
- a carrier liquid having a vapor pressure at 25 ° C and at atmospheric pressure certainly greater than 10,000 Pa (100 mbar), but also less than or equal to 70,000 Pa (700 mbar).
- a carrier liquid which is particularly preferred in the context of the present invention is a hydrofluoroether or a mixture of hydrofluoroethers of formula (1)
- - R H denotes a substituted or unsubstituted, linear, branched or cyclic, partially or fully hydrogenated alkyl radical
- - R F denotes a linear, branched or cyclic, totally or partially fluorinated alkyl radical.
- hydrofluoroethers are very volatile, biocompatible compounds with no toxicity to humans and chemically inert vis-à-vis almost all organic products.
- the HFEs used in the invention are intended to be brought into contact in particular with human tissues.
- RH will preferably be an alkyl radical with a short carbon chain length. Most preferably, the RH radical will be an alkyl with 1 or 2 carbon atoms.
- evaporation times indicated above are average, for 2 ml applied to the skin. They depend in particular on the temperature of the support on which they are applied and can vary depending on the individual, for application to the skin and mucous membranes, depending on body temperature and ambient temperature.
- a pharmaceutical composition as formulated in the invention is particularly suitable for depositing the desired active ingredients on deep wounds, such as wounds of burn victims who can not bear a simple manual pressure to apply a compress.
- the active ingredient is delivered only to the desired site and being in the form of powder, does not flow and does not overflow onto the tissue surrounding the wound.
- the pharmaceutical composition of the invention is a composition for the care of burn victims.
- the pharmaceutical composition of the invention will contain, as active ingredient, any active ingredient which can be put in the form of micronized powder, either by lyophilization, or because it is already synthesized in solid form, or because it will have been put in this form of powder, by lyophilization for example.
- the active ingredient can replace the vaccines currently administered by an injection in the body, insulin which must be immediately released in the body, painkillers for severe pain, antibiotics, anti-asthmatics as well as all cardio-regulators, such than Trinitrine®.
- the dermatological compositions currently formulated with excipients in particular the dermatological compositions containing antibacterial agents, can be formulated by virtue of the invention without any allergenic excipent.
- the active ingredients currently formulated for oral administration may be formulated according to the invention, in the form of a micronized powder in the carrier liquid of the invention.
- These active ingredients may be pain relievers, or iodine tablets.
- nicotine which if administered in this way, may have an immediate effect.
- nicotine can be administered both on the mucous membranes and on the skin, forming a film.
- composition of the invention will also advantageously contain a film-forming agent which will make it possible to keep the nicotine in place on the skin, by forming a protective film on the nicotine.
- hormones currently administered in the form of a patch such as the hormones for treating menopause, may be administered in the form of the composition of the invention, preferably containing a film-forming agent.
- hormones are very difficult to formulate as a patch because they are unstable in current formulations.
- the carrier liquid acts as a transport vehicle to the application site and it is then possible to formulate the composition of the invention in the form of a sprayer whether it is single or multi-dose.
- composition of the invention will consist of 1 to 4 volumes of active ingredient in the form of micronized powder for 4 to 1 volumes of carrier liquid.
- formulations of the pharmaceutical composition of the invention consist of a volume of active ingredient in the form of micronized powder and a volume of carrier liquid.
- HFE do not have any toxicity for humans and are not toxic to the ozone layer and the environment.
- the invention in a second embodiment, relates to biological compositions in which the biological product is in the form of a solid and is insoluble in a carrier liquid which is identical to the carrier liquid described for the pharmaceutical composition according to the first embodiment of the invention. 'invention.
- the invention is based on the use of a carrier liquid as described above for the manufacture of a pharmaceutical and / or biological composition.
- a particularly preferred biological composition in the second embodiment of the invention consists of stem cells from human or animal, or plant tissue.
- the hydrofluoroethers of formula 1 above are cytostatic, which means that any stem cell or living cell will be perfectly preserved and maintained at a certain stage of growth, without being damaged.
- stem cells of living tissue such as human tissue, animal tissue or plant tissue could be prepared in advance at a certain stage of their growth, so that growth can then be continued until the desired stage is reached. by opening the container in which they are packaged in hydrofluoroethers and, as the hydrofluoroether or the mixture of hydrofluoroethers will have immediately volatilized, replace it with a culture medium to continue the growth of these cells.
- stem cells can be used to reconstitute skin on burn victims or to make, very quickly, samples of fresh human skin for the in vitro test of the non-toxicity of cosmetic and / or pharmaceutical products.
- the carrier liquid being volatile, it will be clear to those skilled in the art that the pharmaceutical and / or biological composition of the invention is to be placed in a closed, openable container, possibly resealable, and airtight.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Environmental Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0301761 | 2003-02-13 | ||
FR0301761A FR2851166A1 (en) | 2003-02-13 | 2003-02-13 | Use of perfluorinated volatile liquid in pharmaceutical and/or biological compositions, especially for topical treatment of burns |
PCT/FR2004/050055 WO2004073743A2 (en) | 2003-02-13 | 2004-02-13 | Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1592450A2 true EP1592450A2 (en) | 2005-11-09 |
Family
ID=32749558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04710907A Withdrawn EP1592450A2 (en) | 2003-02-13 | 2004-02-13 | Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions |
Country Status (5)
Country | Link |
---|---|
US (1) | US20060233714A1 (en) |
EP (1) | EP1592450A2 (en) |
JP (1) | JP2006519215A (en) |
FR (1) | FR2851166A1 (en) |
WO (1) | WO2004073743A2 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3476853A (en) * | 1965-04-13 | 1969-11-04 | Colgate Palmolive Co | Sprayed opaque bandage composition |
DE69829280T2 (en) * | 1997-01-30 | 2006-03-30 | Alltracel Development Services Ltd., Sallynoggin | BLOOD-BREEDING AEROSOL PREPARATION |
US5800805A (en) * | 1997-06-19 | 1998-09-01 | Church & Dwight Co., Inc | Aerosol deodorant product |
JP3211740B2 (en) * | 1997-08-28 | 2001-09-25 | ダイキン工業株式会社 | Cosmetics |
FR2782639B1 (en) * | 1998-09-02 | 2002-06-14 | Dehon Sa | REFRIGERANT FOR THE SKIN |
CA2373867C (en) * | 1999-07-02 | 2009-10-13 | The Procter & Gamble Company | Compositions comprising organosiloxane resins for delivering oral care substances |
GB0016876D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
-
2003
- 2003-02-13 FR FR0301761A patent/FR2851166A1/en active Pending
-
2004
- 2004-02-13 WO PCT/FR2004/050055 patent/WO2004073743A2/en active Application Filing
- 2004-02-13 EP EP04710907A patent/EP1592450A2/en not_active Withdrawn
- 2004-02-13 US US10/545,553 patent/US20060233714A1/en not_active Abandoned
- 2004-02-13 JP JP2006502176A patent/JP2006519215A/en active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO2004073743A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP2006519215A (en) | 2006-08-24 |
FR2851166A1 (en) | 2004-08-20 |
WO2004073743A3 (en) | 2004-11-11 |
US20060233714A1 (en) | 2006-10-19 |
WO2004073743A2 (en) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1283704B1 (en) | Pharmaceutical compositions for transdermal administration of anti-inflammatory agents | |
JP5850889B2 (en) | Adhesive skin-forming formulation for skin delivery of drugs and method of using the same | |
CA2330500C (en) | Pharmaceutical compositions capable of being gelled | |
FR2582942A1 (en) | ADHESIVE MEDICAL TAPE FOR ORAL MUCOSA | |
FR2810243A1 (en) | Transdermal patch for delivery of non-steroidal antiinflammatory agent, containing e.g. alkyl-pyrrolidone, metal salt, surfactant and polymers, provides good drug release and absorption properties | |
CA2468018A1 (en) | Micronized film-forming powder comprising an active substance | |
JP5396125B2 (en) | Film-forming formulation | |
FR2698787A1 (en) | Medicinal patches for percutaneous administration. | |
CN109310646A (en) | Enhance the adrenaline composition of delivering | |
EP0817621A1 (en) | Pharmaceutical composition for transdermic delivery | |
LU86457A1 (en) | ENDONASAL APPLICATION SYSTEM | |
LU82364A1 (en) | HEALING PHARMACEUTICAL COMPOSITION CONTAINING AN ANTIFUNGAL / ANTIBACTERIAL AGENT AND SUGAR, AND APPLICATIONS THEREOF | |
JP2020535162A (en) | Enhanced delivery epinephrine and prodrug compositions | |
FR2612785A1 (en) | SELF-ADHESIVE DEVICE FOR DELIVERY OF A PERCUTANEOUS ACTIVE INGREDIENT | |
EP2254551B1 (en) | Sterilized sucralfate gel | |
FR2462424A1 (en) | COMPOSITION BASED ON BENZYL PEROXIDE, IN PARTICULAR FOR THE TREATMENT OF ACNE | |
WO2004073743A2 (en) | Use of a volatile liquid at atmospheric pressure and ambient temperature for the production of pharmaceutical or biological compositions | |
EP1732525B1 (en) | Amorolfine patch for treating onychomycosis | |
FR2686251A1 (en) | COMPOSITION FOR THE HEALING OF A WOUND. | |
BE1028251B1 (en) | SLOW RELEASE MEDICAL PLASTER | |
EP0721327B1 (en) | Aerosol composition for forming a preferably hydrated membrane, preferably hydrated membrane so obtained, and applications thereofparticularly as a dressing | |
EP3829601B1 (en) | Injectable and prolonged action compositions for use in the treatment of diseases of the nail | |
KR100294874B1 (en) | New soft hydrogel type external formulation and production thereof | |
EP3603650A1 (en) | Injectable and prolonged action compositions for use in the treatment of diseases of the nail and/or to accelerate nail growth | |
FR2739030A1 (en) | USE OF A COPOLYMER OF VINYL ACETATE AND N-VINYL-2-PYRROLIDONE IN A TRANSDERMAL MATRIX SYSTEM |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050809 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
DAX | Request for extension of the european patent (deleted) | ||
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HUART, JEAN-JACQUES Inventor name: ZAMBAUX, JEAN-PASCAL Inventor name: ASSIE, JEAN-LOUIS |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: HUART, JEAN-JACQUES Inventor name: ZAMBAUX, JEAN-PASCAL Inventor name: ASSIE, JEAN-LOUIS |
|
17Q | First examination report despatched |
Effective date: 20080723 |
|
111L | Licence recorded |
Free format text: 0101 D-LAB Effective date: 20081001 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: DELVIEL TAIKI |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20130205 |